Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
44.45
-2.20 (-4.72%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Harrow Revenue
Harrow had revenue of $44.20M in the quarter ending March 31, 2026, a decrease of -7.59%. This brings the company's revenue in the last twelve months to $268.68M, up 26.22% year-over-year. In the year 2025, Harrow had annual revenue of $272.30M with 36.41% growth.
Revenue (ttm)
$268.68M
Revenue Growth
+26.22%
P/S Ratio
6.17
Revenue / Employee
$720,308
Employees
373
Market Cap
1.66B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 272.30M | 72.69M | 36.41% |
| Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
| Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
| Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
| Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
| Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
| Dec 31, 2019 | 51.17M | 9.79M | 23.67% |
| Dec 31, 2018 | 41.37M | 14.60M | 54.52% |
| Dec 31, 2017 | 26.77M | 6.83M | 34.26% |
| Dec 31, 2016 | 19.94M | 10.23M | 105.25% |
| Dec 31, 2015 | 9.72M | 8.06M | 485.30% |
| Dec 31, 2014 | 1.66M | -8.34M | -83.40% |
| Dec 31, 2013 | 10.00M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.53B |
| Perrigo Company | 4.18B |
| Phibro Animal Health | 1.50B |
| Trulieve Cannabis | 1.17B |
| ANI Pharmaceuticals | 923.71M |
| BioCryst Pharmaceuticals | 885.72M |
| Collegium Pharmaceutical | 796.33M |
| Alvotech | 562.04M |
HROW News
- 21 hours ago - Harrow and Samsung Bioepis present interim BYOOVIZ post-marketing data - TheFly
- 23 hours ago - Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 - GlobeNewsWire
- 1 day ago - Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting - GlobeNewsWire
- 19 days ago - Harrow announces commercial launch of Byooviz in the U.S. - TheFly
- 20 days ago - Harrow announces commercial launch of BYOOVIZ in U.S. - TheFly
- 20 days ago - Harrow Announces Commercial Launch of BYOOVIZ® in the United States - GlobeNewsWire
- 20 days ago - Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow - Business Wire
- 5 weeks ago - Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare - GlobeNewsWire